| Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy |
115 |
| Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer |
63 |
| CircRNAs and cancer: Biomarkers and master regulators |
54 |
| Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics |
50 |
| Glioma epigenetics: From subclassification to novel treatment options |
50 |
| Prognostic and predictive biomarkers in breast cancer: Past, present and future |
47 |
| PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux |
46 |
| Emerging targets in cancer immunotherapy |
45 |
| Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments |
40 |
| Therapy resistance mediated by cancer stem cells |
39 |
| PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside |
37 |
| Epigenetic drivers of tumourigenesis and cancer metastasis |
36 |
| P21 activated kinase signaling in cancer |
36 |
| Lung cancer epigenetics: From knowledge to applications |
35 |
| Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression |
30 |
| Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance |
28 |
| Phosphatidylserine: A cancer cell targeting biomarker |
27 |
| CRISPR/Cas9 for cancer research and therapy |
27 |
| Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells |
26 |
| Cancer cell plasticity: Impact on tumor progression and therapy response |
25 |
| FoxM1: Repurposing an oncogene as a biomarker |
24 |
| Akt in cancer: Mediator and more |
24 |
| Matrix Metalloproteinases: A challenging paradigm of cancer management |
24 |
| The multiverse nature of epithelial to mesenchymal transition |
24 |
| Breast cancer stem cells: Features, key drivers and treatment options |
24 |
| Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies |
24 |
| Re-evaluating the role of FOXOs in cancer |
23 |
| mTOR: Role in cancer, metastasis and drug resistance |
23 |
| Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment |
23 |
| The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance |
22 |
| Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning |
22 |
| AGEs, RAGEs and s-RAGE; friend or foe for cancer |
22 |
| Genomics and emerging biomarkers for immunotherapy of colorectal cancer |
22 |
| Comparison of glioblastoma (GBM) molecular classification methods |
21 |
| Ras and Rap1: A tale of two GTPases |
21 |
| Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer |
21 |
| Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights |
20 |
| Oxidative stress-modulating drugs have preferential anticancer effects - involving the regulation of apoptosis, DNA damage, endoplasmic reticulum stress, autophagy, metabolism, and migration |
20 |
| Epigenetics in ovarian cancer |
19 |
| Mechanisms of PTEN loss in cancer: It's all about diversity |
19 |
| Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities |
19 |
| Clinical applications of gut microbiota in cancer biology |
18 |
| Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy |
18 |
| Patient-derived tumor organoids for prediction of cancer treatment response |
18 |
| Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs |
17 |
| Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine |
17 |
| The circulating transcriptome as a source of cancer liquid biopsy biomarkers |
17 |
| New biomarkers for diagnosis and prognosis of localized prostate cancer |
17 |
| PIK3CA in cancer: The past 30 years |
17 |
| PDK1: At the crossroad of cancer signaling pathways |
16 |
